PNC
49
3
WU
16
4
HST
57
4
ADSK
63
2
MCK
59
3
KEY
27
3
FLR
52
2
PFG
30
3
WFC
60
2
IP
56
6
F
40
2
USB
50
4
ITW
48
5
AME
50
3
MMC
50
4
VRTX
49
2
SPG
50
4
LOW
46
3
CMG
64
3
KMB
31
3
PNC
49
3
WU
16
4
HST
57
4
ADSK
63
2
MCK
59
3
KEY
27
3
FLR
52
2
PFG
30
3
WFC
60
2
IP
56
6
F
40
2
USB
50
4
ITW
48
5
AME
50
3
MMC
50
4
VRTX
49
2
SPG
50
4
LOW
46
3
CMG
64
3
KMB
31
3
Financhill
Back

Protagonist Therapeutics 10K Form

Sell
42

PTGX
Protagonist Therapeutics

Last Price:
$39.25
Seasonality Move:
28.98%

7 Day Trial

ALL ACCESS PASS

$ 7

Key Filings

2023-11-02 10Q PTGX/Protagonist Therapeutics Quarterly
2023-08-03 10Q PTGX/Protagonist Therapeutics Quarterly
2023-05-04 10Q PTGX/Protagonist Therapeutics Quarterly
2022-11-08 10Q PTGX/Protagonist Therapeutics Quarterly
2022-08-04 10Q PTGX/Protagonist Therapeutics Quarterly
2022-05-05 10Q PTGX/Protagonist Therapeutics Quarterly

Receive PTGX News And Ratings

See the #1 stock for the next 7 days that we like better than PTGX

PTGX Financial Statistics

Sales & Book Value

Annual Sales: $60M
Cash Flow: $-28.6M
Price / Cash Flow: 10.59
Annual Sales: $8.94
Price / Book: 4.4

Profitability

EPS (TTM): 2.66000
Net Income (TTM): $170.8M
Gross Margin: --
Return on Equity: 37.59%
Return on Assets: 33.69%

Protagonist Therapeutics Earnings Forecast

Key Protagonist Therapeutics Financial Ratios

  • The Research & Development expenses have been 200.27% of Revenue.
  • The Interest Expense is 0.00% of Operating Income.
  • The Net Earning history of PTGX is -131.59% of Total Revenues.
  • Per Share Earnings over the last 10 years have been positive in 5 years.

Protagonist Therapeutics Stock Price Chart

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Biotechnology
Sector: Health Care
Current Symbol: PTGX
CUSIP: 74366E
Website: protagonist-inc.com

Debt

Debt-to-Equity Ratio: 0
Current Ratio: 10.7
Quick Ratio: 10.57

Price-to-Earnings

Trailing P/E Ratio: 0
Forward P/E Ratio: 0

PTGX Technical Analysis vs Fundamental Analysis

Sell
42
Protagonist Therapeutics (PTGX) is a Sell

Is Protagonist Therapeutics a Buy or a Sell?